Get started

ABT

ABT to 3.67I like ABT's tokenomics with about 98 million in circulation. It was a great play earlier in the crypto bull cycle and I think early profit takers will jump back in as we move towards $5.00 later this year (Nov). My short term targets for price (on the daily) are around 2.85 to 3.67. It has consolidated well, we've seen recent buy signals kick based on technicals, and it looks to me we are moving away from peak fear towards the greed zone. I bought and am buying at 1.62 to 2.07. This is a really long swing trade that I'll be nibbling at on pullbacks till it's above five dollars. Personally, I like to sell into peak greed and top off my positions on hard pullbacks during peak fear cycles. I'll be watching the daily for invalidation of my targets but I think we've got, at least, a week or two of upward momentum coming.
COINBASE:ABTUSDLong
by DClayton
2
Arcblock triggering a h&s breakdown on the 4hr chart.If it reached the full breakdown target it will head to 3.12. However being a smaller time frame and a bearish pattern in the middle of a bull market cycle, it does decrease the odds of it hitting the full target. I think 3.12 would make for a solid correction for ABT after making such excellent gains the past few months. I do still think after it finishes this correction it is still likely to hit the full measured move target of the log chart bull flag it broke up from awhile back and that this bear pattern breakdown is simply a correction along the way. *not financial advice*
COINBASE:ABTUSD
by DrDovetail
2
ABTUSD Breaking upward from a bull pennantIt looks like it is validating the break upward, full emasured move target can lead to 180% gains from current price range. Of course always possible it corrects all the way back don to the top trendline of the pennant before reaching the full target. If so that’s simply an opportunity to enter at a zone with even bigger gains potential. It could just as easily keep pumping until it reaches the full target as well. If longer consolidation it could take 1 as many as 1-3 weeks to reach the full target also…and then of course a possibility with the least probability as it somehow does a 180 and doesnt reach the full target as all since anything’s possible…but as I said, that scenario is the one with the lowest probability at the moment. *not financial advice*
COINBASE:ABTUSD
by DrDovetail
2
Abbott Laboratories Shows Resilience with Strong Q1 Performance In the dynamic landscape of healthcare, Abbott Laboratories (NYSE: NYSE:ABT ) stands out with its robust first-quarter performance, showcasing resilience and adaptability amidst challenging conditions. Bolstered by a surge in medical device sales and buoyed by promising growth across multiple sectors, Abbott has exceeded expectations and raised its annual guidance, signaling confidence in its trajectory. Let's delve deeper into the factors driving Abbott's success and the implications for investors. 1. Medical Devices Lead the Charge: Abbott's ( NYSE:ABT ) first-quarter success story is largely attributed to the stellar performance of its Medical Devices segment, which witnessed a remarkable organic growth of 14.3%. The star performer within this segment was FreeStyle Libre, demonstrating a phenomenal 23.3% organic growth, underscoring the growing demand for innovative healthcare solutions. 2. Diversification Pays Off: Abbott's diversified portfolio, spanning Established Pharmaceuticals, Nutrition, and Diagnostics, was pivotal in driving overall growth. With double-digit organic growth in Established Pharmaceuticals and substantial gains in Nutrition and Diagnostics, Abbott has showcased its ability to capture opportunities across various healthcare segments. 3. Strategic Innovations: The approval of Abbott's Heart Valve Repair Device by the FDA marks a significant milestone, reinforcing the company's commitment to advancing medical technology. This breakthrough underscores Abbott's relentless pursuit of innovation to address critical healthcare needs, thereby positioning the company for sustained growth and market leadership. 4. Earnings Beat and Guidance Revision: Abbott's impressive adjusted diluted earnings per share of $0.98 not only surpassed analyst estimates but also instilled confidence in the company's financial performance. The upward revision of its fiscal year 2024 adjusted EPS guidance to $4.55-$4.70 reflects management's bullish outlook and underscores Abbott's strong growth prospects in the coming quarters. 5. Market Response and Outlook: Despite the premarket dip in NYSE:ABT shares, Abbott's robust performance and revised guidance signal a compelling investment opportunity. With a solid foundation, innovative pipeline, and optimistic outlook, Abbott is poised to navigate uncertainties and deliver sustainable value to shareholders in the long term.
NYSE:ABT
by DEXWireNews
IRTC Med Tech Device Manufacturer at Fair Value LONGIRTC on the weekly chart shows a symmetrical triangle with compression of price into the apex confluent with the 5 year anchored mean VWAP. I am very familiar with the product line including often lifesaving technology such as AEDs. The company has had weak earnings reports but price has managed to so from undervalued to fair value. I will add to my position here with 20% more. Targets of 140 and 205 are tool drawn onto the chart from pivots of the past. Medical technology is reportedly a hot sector for 2024.
NASDAQ:IRTCLong
by AwesomeAvani
ABT has good news synchronously with price action dip LONG ABT on the one-hour chart is in a sideways diverging channel with Bollinger Bands overlaid and now compressing. In Europe, the new implantable cardiac monitor has tentative approval producing a growth narrative. Relative volumes and volatility have decreased heading into the pivot. ABT is in what is projected to be one of the hottest sectors this year. It pays dividends consistently. I am taking a long trade here. Targets are $120 and $130. A predictive algo validates the idea in its forecast
BITSTAMP:ETHUSD
by AwesomeAvani
ABT/USD - One more push?Today we are looking at ArcBlock What is ArcBlock?: ArcBlock is a platform designed to make building decentralized applications (dApps) easier. It provides developers with tools and resources to create and deploy blockchain-based apps quickly. ArcBlock features include a protocol for connecting to different blockchains, reusable components called Blocklets for adding functionality, decentralized identity management, and a marketplace for sharing and monetizing assets. Its goal is to simplify blockchain development and adoption by providing a user-friendly platform for developers. Exchanges where you can find ArcBlock: Bitget, Coinbase and Gate.io Targets are on chart and stop loss as well. Bought in at current price. Not financial advice, dyor. Have a chart to share? Feel free to drop it down in the comments! Want me to check a chart for you? Let me know in the comments as well!
COINBASE:ABTUSDLong
by DenseCapital
$ATB WavesI like to call this chart ArcBlock Growth Waves. We can see it clearly on the 4 hour chart. Following what we can have in the MACD and SMI indicators, (what I call) Sell Wave 1 ended around .47 cents and dropped to .30 cents, a whole 35% move. Then we had Buy Wave 1, where we ran 400% from the top of Sell Wave 1, to $1.60. We just experienced Sell Wave 2. This was a deeper pull back with a 51% drop. I believe we just entered into the next Buy Wave 2, and we could go as high as 6-7$ range if the pattern continues. This would have to happen in the short term time frame we are entering. So take this post as a call to action. Cheers, trad3zz
Long
by trad3zz
Abbott Laboratories (ABT) Navigating Earnings Abbott Laboratories ( NYSE:ABT ) recently reported earnings that slightly missed expectations at the midpoint, causing a 3.3% dip in NYSE:ABT stock to $110.21. However, a closer look at the results reveals a more nuanced story. Despite the earnings guidance falling short by three pennies at $4.60 per share for the year, the health care giant remains resilient, projecting a robust 8% to 10% organic sales growth. Investors should pay attention as NYSE:ABT stock forms a saucer base with a potential buy point at $115.83. Strong Growth in Medical Devices: One of the key drivers behind Abbott's solid performance was the outstanding growth in its medical devices segment. Sales in this category surged 15.4% organically to $4.44 billion. Notably, the diabetes division played a significant role, with revenues reaching $1.55 billion, marking a substantial 20.7% increase. The star performer in this space was Abbott's body-worn glucose monitor, FreeStyle Libre, which contributed $1.4 billion in sales, up by an impressive 23.8% on an organic basis. Electrophysiology Segment Shines: Another highlight for Abbott ( NYSE:ABT ) was the electrophysiology segment, where revenue grew 15.9% organically to nearly $2.2 billion. This growth is particularly noteworthy considering the challenges posed by a new technology called pulsed field ablation (PFA), which is emerging in the electrophysiology testing space. Analysts believe that Abbott's robust performance in this segment allays fears of losing market share to PFA, underscoring the company's adaptability and resilience. Rapid Diagnostics Faces Headwinds: While Abbott ( NYSE:ABT ) celebrated success in medical devices and electrophysiology, the rapid diagnostics segment faced headwinds. Excluding Covid tests, sales declined by 13.7% to $862 million. The decline was attributed to a later-than-expected flu season, with cases spiking in January. Despite this setback, core lab sales managed to climb 9.7% to $1.37 billion, showcasing the diversified portfolio and the ability to navigate challenges. Conclusion: Abbott Laboratories' ( NYSE:ABT ) recent earnings report might have initially disappointed investors, but a deeper analysis reveals a company that is strategically positioned for growth. With a saucer base forming and a potential buy point at $115.83, savvy investors may see this dip in NYSE:ABT stock as a buying opportunity. Abbott's ability to innovate in the medical devices space, navigate challenges in rapid diagnostics, and shine in electrophysiology suggests that the company is well-poised for sustained success in the dynamic healthcare industry.
NYSE:ABT
by DEXWireNews
Prophet Algo Picks - Jan 24,2024Prophet algo uses markov probabilities to get bullish and bearish probabilities for the day. Uses a custom machine learning algo which backtested gave a 75% win rate when trying to predict daily movements. Definitions: Positive day meaning : When the Closing price for the day is greater than the opening price Negative day meaning : When the Closing price for the day is lower than the opening price Markov model does not care about the intraday price movements, just the difference between opening and closing prices If you would like to analyze intraday movements, use our technical tools, option chain and weekly stock forecasts to get further insights NYSE:ABT Category: Positive Bullish Probability: 82.35% Bearish Probability: 17.65% NYSE:BALL Category: Positive Bullish Probability: 78.05% Bearish Probability: 21.95% NASDAQ:FITB Category: Negative Bullish Probability: 24.49% Bearish Probability: 75.51% NASDAQ:FSLR Category: Negative Bullish Probability: 26.67% Bearish Probability: 73.33% NYSE:GPC Category: Positive Bullish Probability: 76.67% Bearish Probability: 23.33% NYSE:PAYC Category: Positive Bullish Probability: 75.00% Bearish Probability: 25.00% NYSE:VZ Category: Negative Bullish Probability: 15.00% Bearish Probability: 85.00% NYSE:VFC Category: Negative Bullish Probability: 23.08% Bearish Probability: 76.92%
NASDAQ:FSLR
by tradesenigma454
2
ABT Abbott Laboratories Options Ahead of EarningsIf you haven`t sold the regional top on ABT: Nor reentered this fantastic dip: Then analyzing the options chain and the chart patterns of ABT Abbott Laboratories prior to the earnings report this week, I would consider purchasing the 115usd strike price at the money Calls with an expiration date of 2024-2-16, for a premium of approximately $2.26. The chart is overextended and the RSI overbought, but I think there is one more leg to go before a correction. If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
NYSE:ABTLong
by TopgOptions
1
ABT Abbott Laboratories Options Ahead of EarningsIf you haven`t bought ABT here: or sold it here: Then analyzing the options chain and the chart patterns of ABT Abbott Laboratories prior to the earnings report this week, I would consider purchasing the 91usd strike price Calls with an expiration date of 2023-10-27, for a premium of approximately $3.15. If these options prove to be profitable prior to the earnings release, I would sell at least half of them. Looking forward to read your opinion about it.
NYSE:ABTLong
by TopgOptions
2
Abbott Laboratories in a bull flag.Abbott Labratories - 30d expiry - We look to Buy a break of 109.51 (stop at 106.31) The primary trend remains bullish. This stock has seen good sales growth. Expect trading to remain mixed and volatile. 109.34 has been pivotal. Posted a bullish Flag formation. A break of 109.34 is needed to confirm the outlook. The bias is to break to the upside. Our profit targets will be 117.51 and 119.51 Resistance: 108.50 / 109.34 / 112.95 Support: 106.80 / 105.96 / 104.00 Please be advised that the information presented on TradingView is provided to Vantage (‘Vantage Global Limited’, ‘we’) by a third-party provider (‘Everest Fortune Group’). Please be reminded that you are solely responsible for the trading decisions on your account. There is a very high degree of risk involved in trading. Any information and/or content is intended entirely for research, educational and informational purposes only and does not constitute investment or consultation advice or investment strategy. The information is not tailored to the investment needs of any specific person and therefore does not involve a consideration of any of the investment objectives, financial situation or needs of any viewer that may receive it. Kindly also note that past performance is not a reliable indicator of future results. Actual results may differ materially from those anticipated in forward-looking or past performance statements. We assume no liability as to the accuracy or completeness of any of the information and/or content provided herein and the Company cannot be held responsible for any omission, mistake nor for any loss or damage including without limitation to any loss of profit which may arise from reliance on any information supplied by Everest Fortune Group.
NYSE:ABTLong
by VantageMarkets